Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T47594 Target Info
Target Name Activin receptor type IB (ACVR1B)
Synonyms Serine/threonine-protein kinase receptor R2; SKR2; Activin receptor-like kinase 4; Activin receptor type-1B; ALK4; ALK-4; ACVRLK4; ACTR-IB
Target Type Patented-recorded Target
Gene Name ACVR1B
Biochemical Class Kinase
UniProt ID
ACV1B_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9682983
Title BMP inhibitors and methods of use thereof
Abstract The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
Applicant(s) The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
Representative Drug(s) D0F7CA Drug Info IC50 = 1390 nM Click to Show More [1]
2 D05YMG Drug Info IC50 = 3239 nM [1]
3 D01RXV Drug Info IC50 = 6486 nM [1]
Patent ID US9682983
Title BMP inhibitors and methods of use thereof
Abstract The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
Applicant(s) The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
Representative Drug(s) D0F7CA Drug Info IC50 = 1390 nM Click to Show More [1]
2 D05YMG Drug Info IC50 = 3239 nM [1]
3 D01RXV Drug Info IC50 = 6486 nM [1]
Patent ID US9682983
Title BMP inhibitors and methods of use thereof
Abstract The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
Applicant(s) The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
Representative Drug(s) D0F7CA Drug Info IC50 = 1390 nM Click to Show More [1]
2 D05YMG Drug Info IC50 = 3239 nM [1]
3 D01RXV Drug Info IC50 = 6486 nM [1]
Patent ID US10030004
Title Compounds and methods of use
Abstract This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
Applicant(s) Medivation Technologies LLC
Representative Drug(s) D0E9VJ Drug Info IC50 = 11 nM Click to Show More [2]
2 D0Z9FM Drug Info IC50 = 86.8 nM [2]
3 D0IA7H Drug Info IC50 = 89.6 nM [2]
Patent ID US10030004
Title Compounds and methods of use
Abstract This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
Applicant(s) Medivation Technologies LLC
Representative Drug(s) D0E9VJ Drug Info IC50 = 11 nM Click to Show More [2]
2 D0Z9FM Drug Info IC50 = 86.8 nM [2]
3 D0IA7H Drug Info IC50 = 89.6 nM [2]
Patent ID US10030004
Title Compounds and methods of use
Abstract This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
Applicant(s) Medivation Technologies LLC
Representative Drug(s) D0E9VJ Drug Info IC50 = 11 nM Click to Show More [2]
2 D0Z9FM Drug Info IC50 = 86.8 nM [2]
3 D0IA7H Drug Info IC50 = 89.6 nM [2]
References  Top
REF 1 BMP inhibitors and methods of use thereof. US9682983.
REF 2 Compounds and methods of use. US10030004.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.